/stocks — the workspaceLOADING
All SOPHSEC filings, by type → · Earnings date & implied move · Search inside filings
SOPHiA GENETICS SA (SOPH) is a services-computer processing & data preparation company. 43 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
What’s behind SOPH’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
No recent 10-K / 10-Q / 8-K filings found.
Has SOPH been issuing shares? Offering history →
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
A plain-English read on SOPH plus an auto-SWOT — built from SOPH's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate SOPH using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Projected from SOPH's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentSOPH files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| Verma AbhimanyuChief Technology Officer | SELL | $85K | view → |
| HIBBS KATHY LDirector | SELL | $54K | view → |
| Menu PhilippeChief Medical Officer | SELL | $43K | view → |
| Xu ZhenyuChief Scientific Officer | SELL | $163K | view → |
| Valente ManuelaChief People Officer | SELL | $79K | view → |
| Xu ZhenyuChief Scientific Officer | SELL | $30K | view → |
| Menu PhilippeChief Medical Officer | SELL | $38K | view → |
| Camblong JurgiExecutive Chairman | SELL | $209K | view → |
No lawmaker has disclosed a trade in SOPH under the STOCK Act.
| Generation Investment Management (Al Gore) | $39.2M | 0.4% of portfolio |
| Akre Capital Management (Chuck Akre) | $21.5M | 0.4% of portfolio |
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.